Opioid reforms survey
In June 2020, the Federal Government introduced several regulatory changes in relation to the prescribing of opioids for the management of pain.
These changes applied to immediate release and sustained release versions of buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, tapentadol, tramadol and included smaller pack sizes and changes to the authority required for opioids to be subsidised.
More than a year since the reforms were introduced, Painaustralia is keen to hear from consumers living with chronic pain to further understand what impact these changes may have had.
We would like to hear about your experience in the past 18 months, whether there have been any barriers in accessing treatment and how you are coping with any challenges you may have subsequently faced.
Please take our survey, Impact of Opioid changes on people living with chronic pain here